Selective proteasome inhibitors as anti-inflammatory agents

Bibliography

• BARNES PJ, KARIN M: Nuclear factor-x B: a pivotal transcription factor in chronic inflammatory diseases. New. Eng. J. Med. (1997) 336:1066–1071.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of NF-a-dependent pathways in healthand disease.
   Google Scholar
• BALDWIN AS, JR.: The NF-x B and I i B proteins: new discoveries and insights. Ann. Rev. Immunol (1996) 14:649–683.
   PubMed Web of Science ®Google Scholar
• THANOS D, MANIATIS T: NF-x B: a lesson in family values. Cell (1995) 80:1–20.
   PubMedGoogle Scholar
• GRILLI M, CHIU JJ, LENARDO MJ: NF-x B and REL: partici-pants in a multiform transcriptional regulatory system. Int. Rev. Cytol. (1993) 143:1–62.
   PubMed Web of Science ®Google Scholar
• BAEUERLE PA, BALTIMORE D: NF-x B: ten years after. Cell (1996) 87:13–20.
   PubMed Web of Science ®Google Scholar
• PALOMBELLA VJ, RANDO OJ, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-x B1 precursor protein and the activation of NF-x B. Cell (1994) 78:773–785.
   PubMed Web of Science ®Google Scholar
• •One of the first reports that the ubiquitin-proteasome pathway is involved in NF-KB activation.
   Google Scholar
• AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERTG A, KARIN M: Immunosuppression by glucocorticoids: inhibition of NF-x B activity through induction of I K B synthesis. Science (1995) 270:286–290.
   PubMed Web of Science ®Google Scholar
• KOPP E, GHOSH S: Inhibition of NF-x B by sodium salicylate and aspirin. Science (1994) 2651956–959.
   Google Scholar
• SCHEINMAN RI, COGS WELL PC, LOFQUIST AK, BALDWIN AS: Role of transcriptional activation of I K B alpha in mediation of immunosuppression by glucocorticoids. Science (1995) 270:283–286.
   PubMed Web of Science ®Google Scholar
• CHEN Z, HAGLER J, PALOMBELLA VJ et al.: Signal-induced site-specific phosphorylation targets Ix13 alpha to the ubiquitin-proteasome pathway. Genes Develop. (1995) 9:1586–1597.
   PubMed Web of Science ®Google Scholar
• SCHERER DC, BROCKMAN JA, CHEN Z, MANIATIS T, BALLARD DW: Signal-induced degradation of I x B alpha requires site-specific ubiquitination. Proc. Natl. Acad. ScL USA (1995) 92:11259–11263.
   PubMed Web of Science ®Google Scholar
• DIDONATO J, MERCURIO F, ROSETTE C, WU-LI J, SUYANG H, GHOSH S, KARIN M: Mapping of the inducible I K B phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. (1996) 16:1295–1304.
   PubMed Web of Science ®Google Scholar
• HOCHSTRASSER M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Carr. Opin. Biol. (1995) 7:215–223.
   PubMed Web of Science ®Google Scholar
• CIECHANOVER A: The ubiquitin-proteasome proteolytic pathway. Cell (1994) 79:13–21.
   PubMed Web of Science ®Google Scholar
• •Excellent overview of the biology of the ubiquitin-proteasome pathway.
   Google Scholar
• SCHEFFNER M, HUIBREGSTE JM, VIERSTRA RD, HOWLEY PM: THE HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 75:495–505.
   PubMed Web of Science ®Google Scholar
• ROLFE M, BEER-ROMERO P, GLASS S, ECKSTEIN J, BERDO I, THEODORAS A, PAGANO M, DRAETTA G: Reconstitu-tion of p53-ubiquitinylation reactions from purified components: the role of human-ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6A1). Proc. Natl. Acad. ScL USA (1995) 92:3264–3268.
   PubMed Web of Science ®Google Scholar
• SHKEDY D, GONEN H, BERCOVICH B, CIECHANOVER A:Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Lett. (1994) 348:126–130.
   PubMed Web of Science ®Google Scholar
• MURRAY A: Cyclin ubiquitination: the destructive endof mitosis. Cell (1995) 81:149–152.
   PubMed Web of Science ®Google Scholar
• STANCOVSKI I, GONEN H, ORIAN A, SCHWARTZ AL, CIECHANOVER A: Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identificaiton and characterization of the conjugating enzymes. Mol. Cell. Biol. (1995) 15:7106–7116.
   PubMed Web of Science ®Google Scholar
• TREIER M, STASZEWSKI LM, BOHMANN D: Ubiquitin-dependent c-Jun degradation in vivois mediated by the delta domain. Cell (1994) 78:787–798.
   PubMed Web of Science ®Google Scholar
• CHAU V, TOBIAS JW, BACHMAIR A, MARRIOTT D, ECKER DJ, GONDA DK, VARSHAVSKY A: A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science (1989) 24311576–1583.
   Google Scholar
• ADAMS J, STEIN R: Novel inhibitors of the proteasome and their therapeutic use in inflammation. Ann. Reports Med. Chem. (1996) 31:279–288.
   Web of Science ®Google Scholar
• GOLDBERG AL, STEIN R, ADAMS J: New insights into proteasome function: from archaebacteria to drug development. Chem. Biol. (1995) 2:503–508.
   PubMed Web of Science ®Google Scholar
• •Review of proteasome function and drug development.
   Google Scholar
• CHU-PING M, VU JH, PROSKE RJ, SLAUGHTER CA, DEMARTINO GN: Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S protea-some. J. Biol. Chem (1994) 269:3539–3547.
   PubMed Web of Science ®Google Scholar
• LOWE J, STOCK D, JAP B, SWICKL P, BAUMEISTER W,HUBER R: Crystal structure of the 20S proteasome from the archeon T. acidophilum at 3.4 A resolution. Science (1995) 268:533–539.
   Google Scholar
• SEEMULLER E, LUPAS A, STOCK D, LOWE J, HUBER R,BAUMEISTER W: Proteasome from Thermoplasma acidophilum: a threonine preotease. Science (1995) 368:579–582.
   Google Scholar
• MANIATIS T: Catalysis by a multiprotein IKB kinasecomplex. Science (1997) 278:818–819.
   PubMed Web of Science ®Google Scholar
• ORLOWSKI M, CARDOZO C, MICHAUD C: Evidence forthe presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry (1993) 196:1563–1572.
   Google Scholar
• TSUBUKI S, KAWASAKI H, SAITO Y, MIYASHITA N, INOMATA M, KAWASHIMA S: Purification and charac-terization of a Z-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochem. Biophys. Res. Commun. (1993) 196:1195–1201.
   PubMed Web of Science ®Google Scholar
• VINITSKY A, MICHAUD C, POWERS JC, ORLOWSKI M: Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochem-istry (1992) 31:9421–9428.
   PubMed Web of Science ®Google Scholar
• OMURA S, FUJIMOTO T, OTOGURO K et al.: Lactacystin,a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibia (Tokyo) (1991) 441113–116.
   Google Scholar
• OMURA S, MATSUZAKI K, FUJIMOTO T et al: Structure oflactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. J. Antibia (Tokyo) (1991) 44:117–118.
   PubMed Web of Science ®Google Scholar
• FENTEANY G, STANDAERT RF, LANE WS, CHOI S, COREYEJ, SCHREIBER SL: Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 268:726–731.
   PubMed Web of Science ®Google Scholar
• •First report to demonstrate selective inhibition of the protea-some by lactacystin.
   Google Scholar
• SHENVI AB: Alpha aminoboronic acid derivatives:effective inhibitors of aminopeptidases. Biochemistry (1986) 25:1286–1291.
   PubMed Web of Science ®Google Scholar
• KINDER DH, ELSTAD CA, MEADOWS GG, AMES MM: Antimetastic activity of boro-amino acid analog protease inhibitors against B16BL6 melanoma in vivo. Inv. Metastasis (1992) 12:309–319.
   PubMedGoogle Scholar
• PALOMBELLA VJ, CONNER EM, FUSELER JW et al: Role of the proteasome and NF-KB in streptoccoccal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA (1998) 95:15671–15676.
   PubMed Web of Science ®Google Scholar
• ••First demonstration that orally-active proteasome inhibitorattenuates chronic arthritis.
   Google Scholar
• KALOGERIS TJ, LAROUX FS, COCKRELL A et al.: Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am. J. Physiol (1999) 276:C856–C864.
   PubMed Web of Science ®Google Scholar
• READ MA, WHITLEY MZ, WILLIAMS AJ, COLLINS T: NF-KB and kik: an inducible regulatory system in endothe-lial activation. J. Exp. Med. (1994) 179:503–512.
   PubMed Web of Science ®Google Scholar
• CHEN ZJ, PARENT L, MANIATIS T: Site-specific phospho-rylation of ixBcc by a novel ubiquitination-dependent protein kinase activity. Cell (1996) 84:853–862.
   PubMed Web of Science ®Google Scholar
• GLAS R, BOYGO M, MCMASTER JS, GACZYNSKA M, PLOEGH HL: A proteolytic system that compensates for loss of proteasome function. Nature (1998) 392:618–622.
   PubMed Web of Science ®Google Scholar
• SAHNI SK, VAN ANTWERP DJ, EREMEEVA ME, SILVERMANDJ, MARDER VJ, SPORN LA: Proteasome-independent activation of nuclear factor lc B in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsiL Infect. Immun. (1998) 66:1827–1833.
   Google Scholar
• READ MA, NEISH AS, LUSCINSKAS FW, PALOMBELLA VJ,MANIATIS T, COLLINS T: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity (1995) 2:493–506.
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate that the 26S proteasome required for adhesion molecule expression in endothelial cells.
   Google Scholar
• NAUMANN M, SCHEIDEREIT C: Activation of NFicb in vivo is regulated by multiple phosphorylations. EMBO J. (1994) 13:4598–4607.
   Google Scholar
• GRISHAM MB, PALOMBELLA VJ, ELLIOTT PJ et al.: Inhibi-tion of NF-KB activation in vitro and in viva role of 26s proteasome. Meth. Enzymol. (1999) 300:345–363.
   PubMed Web of Science ®Google Scholar
• BRAND SJ, MORISE Z, TAGERUD S, MAZZOLA L, GRANGER DN, GRISHAM MB: Role of the proteasome in rat indomethacin-induced gastropathy. Gastroenter-ology (1999) 116:865–873.
   PubMed Web of Science ®Google Scholar
• ••This study shows the effectiveness of different proteasomeinhibitors to inhibit NSAID-induced gastropathy.
   Google Scholar
• AIKO S, CONNER EM, FUSELER JW, GRISHAM MB: Effects of cyclosporine or flc506 and their vehicles in chronic colitis. J. Pharm. Exp. Therap. (1997) 280:1075–1084.
   PubMed Web of Science ®Google Scholar
• GRISHAM MB, SPECIAN RB, ZIMMERMAN TE: Effects of nitric oxide synthase inhibition on the pathophysi-ology observed in a model of chronic granulomatous colitis. J. Pharm. Exp. Therap. (1994) 271:1114–1121.
   PubMed Web of Science ®Google Scholar
• GRISHAM MB, DEMICHELE SJ, GARLEB KA, SPECIAN RD: Sulfasalazine or enteral diets containing fish oil or oligosaccharides attenuate chronic colitis in rats. Inflamm. Bowel Dis. (1996) 2:178–188.
   PubMed Web of Science ®Google Scholar
• YAMADA T, SARTOR RB, MARSHALL S, SPECIAN RD, GRISHAM MB: Mucosal injury and inflammation in a model of granulomatous colitis in rats. Gastroenter-ology (1993) 104:759–777.
   PubMed Web of Science ®Google Scholar
• CONNER EM, BRAND S, DAVIS JM: Proteasome inhibi-tion attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J. Pharm. Exp. Therap. (1997) 282:1615–1622.
   PubMed Web of Science ®Google Scholar
• •First study to demonstrate that an orally-active proteasome inhibitor (PS-341) tenuates chronic gut inflammation.
   Google Scholar